Suven Life Sciences Quarterly Results for Trading Insights
In Mar 2026, Suven Life Sciences (SUVEN) reported revenue ₹8 Cr and net profit ₹-46 Cr — revenue +166.7% YoY. Compare with Suven Life Sciences valuation methods to assess whether the stock is under or overvalued.
SUVEN Quarterly Results — Revenue, Profit & EPS Highlights
Suven Life Sciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore SUVEN price trends to track price trends across different timeframes.
- Revenue of ₹8 Cr in Mar 2026 (+60.0% vs Sept 2025, +166.7% vs Mar 2025)
- Net Profit of ₹-46 Cr in Mar 2026 (+40.3% vs Sept 2025, -4.5% vs Mar 2025)
- EBITDA of ₹-44 Cr in Mar 2026 (+42.1% vs Sept 2025)
- Operating Margin of -3331.0% in Mar 2026 (+5340.0pp vs Sept 2025)
- Earnings Per Share of ₹-2.02 in Mar 2026 (+42.0% vs Sept 2025)
Suven Life Sciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SUVEN quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 8 | 5 | 3 | 3 | 6 | 60.0% | 166.7% |
| Net Profit (₹ Cr) | -46 | -77 | -44 | -52 | -102 | - | - |
| EBITDA (₹ Cr) | -44 | -76 | -43 | -50 | -101 | - | - |
| EPS (₹) | -2.02 | -3.48 | -2.02 | -2.36 | -4.55 | - | - |
| Operating Margin (%) | -3331.0% | -8671.0% | -2981.0% | -2714.0% | -3678.0% | - | - |
SUVEN Share Price Trend — 1-Year Movement Across Quarterly Results
Suven Life Sciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SUVEN screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SUVEN vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Suven Life Sciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹442,581.33 Cr | 1844.3 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 163.2 |
|
Divis Laboratories
Mar 2026 |
₹179,363.85 Cr | 6797.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 240.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹153,579.77 Cr | 4537.8 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 394.2 |
|
Cipla
Mar 2026 |
₹114,559.46 Cr | 1418.2 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 206.4 |
|
Dr Reddys Laborator…
Mar 2026 |
₹110,089.41 Cr | 1319.0 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.7 |
All amounts in ₹ Crores